This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Strong demand for small molecules as treatment for non-small cell lung cancer (NSCLC) in the eight major markets means that the small molecule treatment market for the disease is expected to reach over $15 billion by 2029. billion and a market share of 17 percent by 2029, GlobalData predicted. percent by 2029.
The passage of the Inflation Control bill is an excellent first step in limiting high drug costs, but our healthcare system is still built for profit at the expense of patients. Patients and doctors are tired, and insurance companies are raising rates after two years of making a surplus because nobody went to the doctor during the pandemic.
Personalized Medicine Thanks to AI, we will create simulations of the human body at the molecular, cellular and organ levels, allowing treatments to be personalized for each patient. This will lead to treatments that are more effective and safer, as the specificities of each patient will be taken into account.
In 2022, the FDA awarded VX-548 breakthrough therapy and fast-track designations for post-operative pain, and the drug is forecast to reach sales of $416m by 2029. A promising example includes Vertex Pharmaceuticals’s VX-548, a sodium channel subunit blocker. Six cannabinoids have recently completed or are undergoing Phase II trials.
Small molecule treatment TAGRISSO ® (osimertinib) demonstrated a “statistically significant and highly clinically meaningful improvement” in progression-free survival (PFS) for Stage III lung cancer patients, AstraZeneca has confirmed. This was established from positive high-level results seen in the LAURA Phase III trial.
The construction projects will be finalised from the end of 2025 through to 2029. This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide”, Wulff declared in the original annoucement.
Dr John Lin, senior vice president of immune-oncology and head of bispecifics at Regeneron , said: “The collaboration will enable Regeneron and CytomX to combine our collective oncology expertise with two premier platforms […] to develop novel immunotherapies and research their potential to transform patient lives.”.
This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide,” stated Henrik Wulff, executive vice president of Product Supply, Quality & IT at Novo Nordisk. The facility is expected to start producing API by early 2029.
The first patient has already been enrolled into its FIBRONEER phase 3 programme for BI 1015550, which already has a breakthrough designation from the FDA after a positive phase 2 trial showed improved lung function in patients with IPF over a 12-week period. There are more than 200 lung disorders that can lead to pulmonary fibrosis.
As a “vital class of treatments” for patients worldwide, King considered that the new legislation would “fix a section of the US Inflation Reduction Act (IRA) and make certain that we are not disincentivising the development of small molecule drugs that are often more accessible for patients”.
These new treatments hold tremendous promise to advance patient care and fuel the next generation of medical breakthroughs. Clarivate data indicates a 90% probability that datopotamab deruxtecan will win marketing authorization in the United States, and projects 2029 sales of $2.7 billion in 2029 for CASGEVY alone.
AstraZeneca highlighted that beneficially, the Gracell FasTCAR platform significantly shortens manufacturing time, enhances T cell fitness and could improve the effectiveness of autologous CAR-T treatment in patients. According to the research, the global cell and gene therapy market is predicted to value $80 billion by 2029.
In 2022, US sales of Ozempic contributed to 65% of global sales; this is expected to continue, with the US market forecast to continue capturing the majority of sales, generating $71bn between 2023–2029. It is forecast that Ozempic will sustain its sales growth over the next five years, with an expected annual sales figure of $17bn in 2029.
Yet as the market continues to recognise the value of these treatments, especially with them having “clear benefits over current monotherapy and combination therapy options in cancer treatment”, it is unsurprising that GlobalData’s research predicted the ADC oncology therapy market will value more than $36 billion by 2029.
The agent is being evaluated in relapsed/refractory (R/R) patients who have KMT2A-rearranged (KMT2ar) or NPM1-mutant (NPM1m) acute myeloid leukaemia (AML). Ziftomenib targets the menin-KMT2a protein-protein interaction that may occur in patients with KMT2ar or NPM1m genetic alterations. months for all patients achieving CRc.
There, the data shows that patients on this regimen live longer lives along with having a greater period of time before disease progression, than with other treatments. CLL is regarded as the most common type of leukaemia in England where 3,157 patients were diagnosed with the disease in 2017, based on the institute’s announcement.
According to Maximize Market Research , new technologies are expected to boost the clinical trials market between 2022 to 2029, especially as the industry and patients are shifting towards digitalisation approaches and personalised medicines.
The company predicted this will be “driven by an increase in the patient share of dual orexin receptor antagonists (DORAs)”. In the US in 2029 and in Japan in 2031, Belsomra is set to lose market exclusivity. percent from $3.2 billion in 2022 to $4.1 billion in 2032. percent between 2022 and 2032. million in sales by 2032.
In recent years, gene therapy has transitioned from a promising idea to a reality for patients, with many of the severe safety issues that emerged in early iterations of the technology being overcome. from 2021 to 2029. FDA backing. A broadening pipeline.
billion by 2029. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021. The device replaces a connecting bone in the ankle joint and can be customized according to patient preference.
In May 2021, Amgen’s Lumakras was approved for use in adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). billion in 2029. According to a consensus forecast from GlobalData’s Pharma Intelligence Centre, Lumakras, also known as sotorasib, has projected sales of $1.47
Blincyto has provided a strong positive signal to demonstrate the clinical and commercial viability of BiTEs, with 2021 company-reported global sales of $542 million and GlobalData’s analyst consensus forecast projecting peak annual sales of $771 million by 2029, thereby sparking further industry interest in this field. months vs. 4.0
It was about solving cold-chain logistical challenges and ensuring the vaccine doses themselves could be administered easily and efficiently with minimal discomfort for patients. million by 2029, up from $122.287 million in 2021. We have been given a crash course in how to deliver vaccine doses successfully to billions of people.
Wedbush Securities recently forecast more than $1 billion in 2029 sales for ensifentrine in the US alone, assuming a launch in the first quarter of 2024, and said today the stock could easily reach $30. Shares in Verona popped on the news, rising more than 40% to approach $19.50 and drive the company’s market cap to almost $1.5
The phase 3 ESCAPE-TRD study in 676 patients revealed that significantly more of those treated with Spravato were able to achieve remission from symptoms of depression without a relapse over 32 weeks of follow-up compared to quetiapine. and 14.1%, respectively.
Based on GlobalData’s patient-based forecast models, RA and CD are the top two indications contributing to this value, accounting for around 45% and 14%, respectively, of Humira’s sales. According to GlobalData’s Sales and Forecast Consensus database, Humira is anticipated to have garnered sales of $18.6 billion in 2022.
However, Medicare will only be able to negotiate prices for 10 Part D drugs in 2026, another 15 Part D drugs in 2027, another 15 Part D and Part B drugs in 2028, and another 20 Part D and Part B drugs for 2029 and subsequent years. Impact Beyond Medicare The IRA won’t just impact negotiation with the government either. Reference: 1.
billion by 2029. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021. The device replaces a connecting bone in the ankle joint and can be customized according to patient preference.
This helps patients, businesses and doctors alike by settling expectations and creating a more efficient system for gathering, reporting and understanding such data.” The bill mostly relates to pharmaceutical companies, and the new amendments due to come in place in 2011 could impose further regulation.
Many of the current existing therapies are often viewed by physicians as not optimal to addressing the needs of patients, and challenges remain such as improving patient compliance, safety profile, and addressing comorbidities of T2D. billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%.
Type 1 diabetes (T1D) is forecast to affect five million people in the eight major pharmaceutical markets, which are the US, France, Germany, Italy, Spain, UK, Japan, and Canada, by 2029. The spokeswoman goes on to say that these savings are not shared with the patients, who end up paying more for insulin than their insurance company.
Clinical benefits seen in the obicetrapib Phase II ROSE2 trial In the Phase II ROSE2 trial, patients received a combination therapy of 10mg of obicetrapib or placebo for 12 weeks. LDL-C levels were observed to lower in 88 percent of patients to less than 55mg/dL. At 12 weeks, LDL-C was reduced by 43.5 percent and 40.2
The FDA’s decision means that patients with advanced Epstein–Barr virus-related cancers will be given another treatment option. billion by 2029. The US Food and Drug Administration (FDA) has granted the first approval of an Epstein–Barr virus-related mRNA therapeutic cancer vaccine.
billion by 2029. This requires modulating different components of the human immune system in a way that can address different patient segments, as the immune system is dysregulated in different ways across different tumour types. According to Data Bridge Market Research, the haematology /oncology market will value $14.83
GlobalData forecasts Rituxan sales to plummet to just over $300m by 2029, while biosimilars will collectively surpass $1bn in sales in the same year, becoming responsible for nearly 80% of the total market share for rituximab products.
of NSCLC patients with exon 19 and 21 mutations develop resistance mutations at C797S. billion in 2029. More specifically, STX-241 targets exon 19 and exon 21 mutations alongside the co-occurring C797S mutation, whereas STX-721 focuses on exon 20 mutations. Up to 12.5% GlobalData is the parent company of Pharmaceutical Technology.
billion by 2029, with the new facility set to secure the long-term supply of insulin for diabetic patients and “strengthen European security of supply”, the company added. Sanofi is planning to construct a new insulin production facility at its BioCampus in Frankfurt Höchst, Germany. The investment will total approximately €1.3
Any company that could provide DMTs would have ample opportunities for market entry, as they could bring about a major shift in patient treatment. The US market is driving this growth, forecasted to nearly triple from $2.4bn in 2023 to $7.4bn by 2029, as per GlobalData. GlobalData is the parent company of Pharmaceutical Technology.
Orphan drug designations are granted to drugs that target rare disorders with fewer than 200,000 patients in the US. Primary biliary cholangitis is a rare autoimmune disease where small bile ducts are injured by the patient’s own immune system. billion in 2029. The condition gradually worsens and can result in liver failure.
Pre-waiver, for behavioral health visits, patients were required to have received an in-person evaluation six months before initiating telehealth, followed by an in-person visit annually. Waivers enable access to medications for hundreds of thousands of patients nationwide for a variety of medical diagnoses including substance use disorder.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content